To evaluate the utility of the systemic immune inflammation index (SII) and systemic inflammation response index (SIRI) in diagnosing pulmonary embolism (PE) in emergency medicine.We retrospectively reviewed the data of patients who presented to the emergency ...

Background and Objectives: This study aimed to evaluate the diagnostic value of oxidative stress parameters in fibromyalgia syndrome (FMS) and to investigate their potential associations with disease severity, functional impairment, anxiety, and depression. Materials and Methods: The study included 84 participants, consisting of 42 women diagnosed with fibromyalgia (FM) and 42 healthy female controls. Serum levels of total antioxidant status (TAS), total oxidant status (TOS), and malondialdehyde (MDA) were measured in all participants, and the oxidative stress index (OSI) was calculated. Additionally, the Fibromyalgia Impact Questionnaire (FIQ), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI) were administered to assess mental health and functional status. Results: The levels of TOS, TAS, MDA, and the OSI were significantly higher in the fibromyalgia group compared to the control group (p < 0.001). The relationship between TAS, TOS, MDA, and OSI levels and BDI, BAI, and FIQ scale scores was investigated in the case group, but no significant associations were identified between oxidative stress markers and psychological or functional scores. When all participants were analyzed as a single group, significant correlations were found between TAS, TOS, MDA, and OSI levels and several biochemical parameters, including CRP, AST, free T4, HbA1c, ferritin, and folic acid. Conclusions: Our study adds to the growing body of evidence indicating elevated oxidative stress in female patients with fibromyalgia syndrome (FMS) and suggests that TAS, TOS, MDA, and OSI may serve as potential biomarkers for its diagnosis.

Background and Objectives: Diabetic neuropathy (DNP) is the most common complication of diabetes mellitus (DM), and the pathogenesis of DNP involves multiple complex pathways. In this study, we aimed to evaluate whether hematologic and inflammatory parameters, the atherogenic index, and the triglyceride–glucose (TyG) index are useful for clinical use in the development and severity of diabetic polyneuropathy (DNP) in non-diabetic (Non-DM), prediabetic (Pre-DM), and diabetic (DM) patients. Materials and Methods: Patients with Non-DM (n = 62), Pre-DM (n = 97), and DM (n = 327) were included in the study, and laboratory parameters suitable for routine use were analyzed retrospectively. Various inflammatory markers, lipid profiles, and metabolic indicators were evaluated. Results: In prediabetic patients, PNP severity showed a significant positive correlation with age (p < 0.001) and glucose levels (p = 0.020) and a significant negative correlation with LDL levels (p = 0.009). In diabetic patients, there was a positive correlation between PNP severity and age (p < 0.001), neutrophils (p = 0.024), triglycerides (p = 0.012), glucose (p < 0.001), HbA1c (p < 0.001), neutrophil-to-lymphocyte ratio (NLR) (p = 0.001), glucose-to-lymphocyte ratio (GLR) (p < 0.001), triglyceride/HDL ratio (TG/HDL) (p < 0.001), TyG index (p < 0.001), and a significant negative correlation with platelet (PLT) (p < 0.001), HDL (p < 0.001), and lymphocyte-to-monocyte ratio (LMR) (p < 0.001). In addition, age (p < 0.001), GLR (p = 0.027), and TG/HDL (p < 0.001) values were positively correlated, and the TG/glucose ratio (TGR) (p = 0.018) was negatively correlated with PNP severity in Pre-DM and DM patients. Conclusions: Our study suggests that inflammatory markers and lipid indices may play an important role in determining the severity of DNP in Non-DM, Pre-DM, and DM patients. These parameters may offer a new, easy, and low-cost option for assessing the risk of diabetic polyneuropathy.

Objectives: This study aimed to determine whether there is a difference in the electrocardiography (ECG) measurements of healthy controls and rheumatoid arthritis (RA) patients and to predict whether they can be used to determine the risk of arrhythmia in patients. Patients and methods: The prospective study included 50 cardiac asymptomatic RA patients (38 males, 12 females; mean age: 46.8±9.1 years; range, 18 to 60 years) who met the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology RA criteria and 50 healthy volunteers (34 males, 16 females; mean age: 43.4±10.4 years; range, 18 to 60 years) as a control group between June 1, 2022, and August 31, 2022. Disease activity of the patients was calculated with the Disase Activity Score (DAS28). Heart rate, minimum and maximum QT intervals, QT dispersion, minimum and maximum P waves, P wave dispersion (Pd), minimum and maximum Tp-e intervals, Tp-e dispersion, minimum and maximum corrected QT (QTc) intervals, QTc dispersion, and the Tp-e/QTc ratio in ECGs were calculated. Results: The mean disease duration of the RA group was 9.09±5.74 years. The mean C-reactive protein level was 9.83±8.29, the mean erythrocyte sedimentation rate was 26.12±16.28 mm/h, and the mean DAS28 was 3.03±0.37. There was a statistically significant increase in the maximum P wave, Pd, maximum QT, QT dispersion, maximum QTc, QTc dispersion, maximum Tp-e, Tp-e dispersion, and Tp-e/QTc dispersion parameters in the RA group compared to the control group, while there was a significant decrease in the minimum P wave, minimum QT, and minimum QTc parameters. Conclusion: In our study, the Pd, QTc dispersion, Tp-e dispersion, and Tp-e/QTc dispersion values of our patients, which indicate the risk of atrial and ventricular arrhythmia, were found to be significantly higher. This finding suggests that our patients had an increased risk of cardiac morbidity and mortality. Arrhythmias are the likely source of the increase in sudden cardiac death in RA, and these new indicators measured on ECG can be used as standardized cardiovascular morbidity and mortality indicators in the future.

Background and Objectives: This study aimed to evaluate serum asprosin levels in female patients with fibromyalgia syndrome (FM), investigate their associations with clinical parameters such as disease severity, anxiety, and depression, and evaluate the potential of serum asprosin levels as a biomarker for fibromyalgia diagnosis. Materials and Methods: A total of 80 participants were included in the study, 40 women aged 18–60 years who were diagnosed with FM according to the American College of Rheumatology (ACR) 2016 criteria and 40 healthy women with similar sociodemographic characteristics to the patient group. All participants were measured for hemograms, biochemistry tests, and serum asprosin levels. Additionally, the Fibromyalgia Impact Questionnaire (FIQ), Beck Anxiety Inventory (BAI), and Beck Depression Inventory (BDI) were administered to the patient group. Results: The median asprosin level in the case group was 15.01 (SD = 10.08–31.42), while in the control group it was 31.03 (SD = 25.14–35.7). The asprosin levels in the case group were significantly lower than those in the control group (p = 0.001). In contrast, AST, vitamin B12, and folic acid levels were significantly higher in the case group than in the control group. When all participants were evaluated, asprosin levels showed a significant positive correlation with systolic arterial blood pressure (Rho = 0.337, p = 0.002) and diastolic arterial blood pressure (Rho = 0.238, p = 0.033). A cut-off value of 17.72 ng/mL for asprosin levels in the diagnosis of fibromyalgia demonstrated a sensitivity of 60% and a specificity of 90%. Conclusions: Low asprosin levels may serve as a potential biomarker for the diagnosis of fibromyalgia in women.

Objective: The present study aimed to compare C-reactive protein (CRP), neutrophil/lymphocyte ratio (NLR), neutrophil/albumin ratio (NAR), platelet/leukocyte ratio (PLR), systemic immune inflammation (SII), systemic inflammation response index (SIRI) and Ranson criteria associated with inflammation in acute pancreatitis (AP). Thus, the study aimed to analyze the significance ranking of these parameters in terms of disease severity. Method: The present retrospective study was conducted after the ethics committee approval was obtained. The study included 221 AP patients visited hospital between 01.01.2018 and 31.12.2023. The patients were categorized into two groups based on Ranson criteria: Group 1 (Ranson≤2, n=147) and Group 2 (Ranson≥3, n=74). Basic participant demographics, laboratory reports, CRP, NLR, NAR, PLR, SII, SIRI and hospitalization periods were recorded in a data form, and the findings were analyzed. Results: There was no difference between the groups based on gender (p=0.094). The Group 2 patients were older (p<0.001) than the ones in Group 1. Furthermore, CRP (p=0.001), NLR (p<0.001), NAR (p<0.001), PLR (p<0.001), SII (p<0.001) and SIRI (p<0.001) were higher in Group 2 patients when compared to Group 1. Also, the hospitalization period was significantly longer in Group 2 (p<0.001) compared to Group 1. Conclusion: In the study, it was determined that the CRP, NAR, PLR, NLR, SII and SIRI findings were significantly higher in AP patients with a Ranson criteria ≥ 3, and a positive correlation was found between Ranson criteria and inflammatory parameters.